Olema Pharma Q3 net loss $34.6M; cash $214.8M; OP-3136 IND on track

Olema Pharmaceuticals, Inc.

2024-Q3 EPS reported -$1.80

Q3 2024 net loss $34.6M vs $21.5M in Q3 2023; GAAP R&D $33.2M (up from $19.5M).
Cash, equivalents, marketable securities $214.8M as of Sep 30, 2024; no revenue reported.
OPERA-01 Phase 3 palazestrant monotherapy enrolling; top-line readout expected 2026.
IND submission for KAT6 inhibitor OP-3136 expected before year-end; Phase 1 start early 2025.
Updated Phase 2 palazestrant + ribociclib data to be presented at SABCS December 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.